Zoetis Inc.

Equities

ZTS

US98978V1035

Pharmaceuticals

Market Closed - Nyse 16:00:02 2024-05-02 EDT 5-day change 1st Jan Change
167.2 USD +5.51% Intraday chart for Zoetis Inc. +9.04% -15.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Redburn Atlantic Adjusts Price Target on Zoetis to $220 From $230, Keeps Buy Rating MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple... Our Logo
Transcript : Zoetis Inc., Q1 2024 Earnings Call, May 02, 2024
Zoetis' Q1 Adjusted Earnings, Revenue Rise; 2024 Outlook Lowered MT
(ZTS) ZOETIS Expects Fiscal Year 2024 Revenue Range $9.05B - $9.2B MT
(ZTS) ZOETIS Sees Fiscal Year 2024 EPS Range $5.71 - $5.81 MT
Earnings Flash (ZTS) ZOETIS Posts Q1 Revenue $2.19B MT
Earnings Flash (ZTS) ZOETIS Posts Q1 EPS $1.38 MT
Zoetis Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zoetis Inc. Revises Earnings Guidance for the Year 2024 CI
Corn Futures Rise on Potential Planting Delay -- Daily Grain Highlights DJ
Stifel Adjusts Price Target on Zoetis to $180 From $195 MT
Zoetis to Sell Medicated-Feed-Additive Portfolio to Phibro for $350 Million DJ
Zoetis to Sell Medicated Feed Additives Business to Phibro Animal Health for $350 Million MT
Zoetis to sell medicated feed additive portfolio to Phibro in $350 mln deal RE
Phibro Animal Health Corporation entered into a definitive agreement to acquire Medicated feed additive product portfolio, certain water soluble products and related assets of Zoetis Inc. for approximately $350 million. CI
Barclays Adjusts Zoetis' Price Target to $230 From $260, Keeps Overweight Rating MT
Jefferies Lowers Zoetis Price Target to $200 from $220 MT
Zoetis Signs 12-Year Virtual Power Purchase Agreement With Scout Clean Energy MT
Zoetis Inc. Announces Executive Changes CI
Piper Sandler Adjusts Zoetis' Price Target to $195 From $220, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Sector Update: Health Care Stocks Lower Friday Afternoon MT
Sector Update: Health Care MT
Zoetis Shares Fall After Dog Owners Reportedly Blame Arthritis Drug Librela for Pet Illnesses MT
Chart Zoetis Inc.
More charts
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%); - livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%); - other (1.1%). Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%). At the end of 2022, the group has 29 production sites worldwide. The United States accounts for 53.4% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
167.2 USD
Average target price
214.6 USD
Spread / Average Target
+28.33%
Consensus
  1. Stock Market
  2. Equities
  3. ZTS Stock
  4. News Zoetis Inc.
  5. Zoetis Reports Higher Q2 Adjusted Profit, Revenue; Updates 2022 Outlook